Nu Skin Enterprises (NUS) Downgraded by Zacks Investment Research to “Sell”

Share on StockTwits

Zacks Investment Research cut shares of Nu Skin Enterprises (NYSE:NUS) from a hold rating to a sell rating in a report published on Tuesday.

According to Zacks, “Nu Skin’s shares have underperformed the industry in the past three months, thanks to dismal gross margins and adverse impacts from currency fluctuations. In fact, the company’s gross margin has been slipping since the past several quarters. This emerges as a considerable threat to profitability. Moreover, the company’s bottom-line in the third-quarter was hurt by foreign currency translation losses of almost 7 cents. Management expects currency translations to dent earnings in 2018. On the bright side, Nu Skin has been steadily gaining from expanding sales leaders and customers. Notably, these upsides aided third-quarter 2018 results, marking its fourth consecutive period of year-on-year top- and bottom-line increases. The company plans to further empower sales leaders through improved training and technological enhancements. Further, it relies on social media as well as product and marketing programs to widen customer reach.”

Several other equities research analysts also recently issued reports on NUS. Tigress Financial reaffirmed a buy rating on shares of Nu Skin Enterprises in a research note on Wednesday, November 21st. Jefferies Financial Group reaffirmed a buy rating and set a $92.00 price target on shares of Nu Skin Enterprises in a research note on Thursday, November 8th. DA Davidson assumed coverage on shares of Nu Skin Enterprises in a research note on Tuesday, October 9th. They set a buy rating and a $92.00 price target on the stock. Citigroup set a $88.00 price target on shares of Nu Skin Enterprises and gave the stock a buy rating in a research note on Thursday, November 8th. Finally, Bank of America reaffirmed an underperform rating and set a $65.00 price target (down previously from $75.00) on shares of Nu Skin Enterprises in a research note on Thursday, December 6th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Nu Skin Enterprises currently has a consensus rating of Hold and an average price target of $83.63.

Nu Skin Enterprises stock opened at $61.98 on Tuesday. Nu Skin Enterprises has a 12-month low of $56.09 and a 12-month high of $88.68. The firm has a market cap of $3.41 billion, a P/E ratio of 19.19, a PEG ratio of 1.41 and a beta of 0.93. The company has a current ratio of 1.93, a quick ratio of 1.25 and a debt-to-equity ratio of 0.44.

Nu Skin Enterprises (NYSE:NUS) last released its quarterly earnings results on Wednesday, November 7th. The company reported $0.94 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by ($0.02). Nu Skin Enterprises had a return on equity of 27.50% and a net margin of 5.93%. The firm had revenue of $675.31 million for the quarter, compared to analysts’ expectations of $664.99 million. During the same period last year, the firm earned $0.76 EPS. The business’s quarterly revenue was up 19.8% on a year-over-year basis. On average, equities analysts expect that Nu Skin Enterprises will post 3.51 EPS for the current fiscal year.

In other news, General Counsel D Matthew Dorny sold 1,250 shares of the business’s stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $60.60, for a total value of $75,750.00. Following the completion of the sale, the general counsel now owns 32,621 shares of the company’s stock, valued at approximately $1,976,832.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 6,250 shares of company stock valued at $407,925 in the last three months. Insiders own 3.00% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Retirement Systems of Alabama boosted its holdings in shares of Nu Skin Enterprises by 0.4% in the 4th quarter. Retirement Systems of Alabama now owns 72,023 shares of the company’s stock valued at $4,417,000 after buying an additional 260 shares during the period. State of Alaska Department of Revenue boosted its holdings in shares of Nu Skin Enterprises by 3.6% in the 4th quarter. State of Alaska Department of Revenue now owns 13,546 shares of the company’s stock valued at $830,000 after buying an additional 466 shares during the period. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Nu Skin Enterprises by 21.3% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 4,255 shares of the company’s stock valued at $351,000 after buying an additional 746 shares during the period. Harvest Fund Management Co. Ltd boosted its holdings in shares of Nu Skin Enterprises by 162.9% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,291 shares of the company’s stock valued at $106,000 after buying an additional 800 shares during the period. Finally, Arizona State Retirement System boosted its holdings in shares of Nu Skin Enterprises by 2.1% in the 3rd quarter. Arizona State Retirement System now owns 39,429 shares of the company’s stock valued at $3,250,000 after buying an additional 819 shares during the period. 74.57% of the stock is owned by institutional investors and hedge funds.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.

Featured Article: How Short Selling Works

Get a free copy of the Zacks research report on Nu Skin Enterprises (NUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nu Skin Enterprises  Downgraded by Zacks Investment Research to “Sell”
Nu Skin Enterprises Downgraded by Zacks Investment Research to “Sell”
Olin  Stock Rating Lowered by Zacks Investment Research
Olin Stock Rating Lowered by Zacks Investment Research
Nexa Resources  Receives New Coverage from Analysts at BMO Capital Markets
Nexa Resources Receives New Coverage from Analysts at BMO Capital Markets
Pennsylvania R.E.I.T.  Lifted to Hold at Zacks Investment Research
Pennsylvania R.E.I.T. Lifted to Hold at Zacks Investment Research
Brokerages Set Camtek LTD.  PT at $9.44
Brokerages Set Camtek LTD. PT at $9.44
Ixcoin  Trading 1.5% Higher  This Week
Ixcoin Trading 1.5% Higher This Week


Leave a Reply

© 2006-2019 Ticker Report